Race of kidney donors may affect the survival rates of transplant recipients

The race of kidney donors may affect the survival rates of transplant recipients according to a study by Henry Ford Hospital.

"We found that transplant between races had better outcomes than transplant across races," says Anita Patel, M.D., transplant nephrologist at Henry Ford Hospital Transplant Institute and lead author of the study.

"It is important to remember that the statistical difference in this observation is greatly outweighed by the life-giving benefits that recipients get from transplantation."

The study will be presented Oct. 30 at the American Society of Nephrology's Annual Meeting and Scientific Exposition in San Diego by co-investigator Rahul Pandey, M.D., a nephrology fellow.

Using data from the United Network of Organ Sharing (UNOS) of more than 158,000 recipient patients between 1995 and 2008, Henry Ford physicians analyzed the effect of donor/recipient race disparity on patient survival.

By regression analysis, the non-black recipients who received a kidney from black donors had a significant lower survival rate compared to those who received a kidney from a non-black donor (hazard ratio 1.111,>

"Hepatitis C infection in the donor or recipient was seen as a significant risk factor for mortality," says Dr. Patel.

She further explains that because this is an observation from a large, national database, additional analysis of more detailed, targeted data is needed to determine why the difference exists. Her next step involves looking at the effect of peri-transplant factors, transplant type, socioeconomic status, length of dialysis, immunosuppression regimes and other factors on racial disparity and mortality.

Dr. Patel presented a similar study earlier this year which looked at race and the effect on renal allograft survival in different donor/recipients pairs. In that study, Dr. Patel found an increased risk in graft failure in non-black recipients of non-heart beating black donor kidneys. They appeared to have a two-fold increased risk of graft failure.

According to UNOS, more than 16,000 kidney transplants were performed last year. More than 80,000 people are waiting for kidney donors, and last year, 33,000 new kidney patients joined the registry. Twelve percent of living donors are African-American.

Comments

  1. David J Undis David J Undis United States says:

    Your story about the race of Kidney Donors highlighted the tragic shortage of human organs for transplant operations.

    Over half of the 100,000 Americans on the national transplant waiting list will die before they get a transplant.  Most of these deaths are needless.  Americans bury or cremate 20,000 transplantable organs every year.

    There is a simple way to put a big dent in the organ shortage – give donated organs first to people who have agreed to donate their own organs when they die.

    Giving organs first to organ donors will convince more people to register as organ donors.  It will also make the organ allocation system fairer.  People who aren't willing to share the gift of life should go to the back of the waiting list as long as there is a shortage of organs.

    Anyone who wants to donate their organs to others who have agreed to donate theirs can join LifeSharers.  LifeSharers is a non-profit network of organ donors who agree to offer their organs first to other organ donors when they die.  Membership is free at www.lifesharers.org or by calling 1-888-ORGAN88.  There is no age limit, parents can enroll their minor children, and no one is excluded due to any pre-existing medical condition.  LifeSharers has over 13,000 members at this writing.  

    Please contact me - Dave Undis, Executive Director of LifeSharers - if your readers would like to learn more about our innovative approach to increasing the number of organ donors.  I can arrange interviews with some of our local members if you're interested.  My email address is [email protected].  My phone number is 615-351-8622.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR